Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference
November 28, 2022 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29...
Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit
November 14, 2022 16:03 ET
|
Lexicon Pharmaceuticals, Inc.
Achieved primary endpoint for reduction in average daily pain score (ADPS) at week 6Significant benefits demonstrated on burning pain and on pain interference with sleepNo evidence of withdrawal...
Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
November 11, 2022 08:58 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 13th Annual Jefferies London Healthcare Conference,...
Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update
November 09, 2022 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
NDA for Sotagliflozin Remains on Track for May 2023 PDUFA Date Following Mid-Cycle Review Meeting Final Data from Successful RELIEF-DPN-1 Study of LX9211 in Painful Diabetic Neuropathy to Be...
Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit
November 08, 2022 08:58 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the final results from the Phase 2 RELIEF-DPN-1 trial of its investigational...
New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure
November 06, 2022 17:29 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Nov. 06, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes study of...
New Analysis of SCORED Trial Demonstrates Sotagliflozin’s Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
November 05, 2022 10:35 ET
|
Lexicon Pharmaceuticals, Inc.
Post hoc analysis of clinical data from the SCORED trial presented at the American Society of Nephrology Kidney Week 2022 annual scientific meeting, including evidence that: Sotagliflozin...
Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
November 04, 2022 08:58 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2022 financial results on Wednesday, November 9, 2022, after the...
New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022
October 31, 2022 08:59 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF and...
Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022
October 24, 2022 08:59 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug...